View reports from
On November 5, 2019, Karo Pharma Aktiebolag (“Karo Pharma”) issued a press release regarding the Pfizer collaboration and license agreement related to ROR-gamma (“the Pfizer agreement”). The press release informed of Pfizer’s decision to terminate a specific development project, PF-06763809. Karo Pharma has now decided to issue further clarifications on the matter. The supplementary information...
Read moreThe updated shareholder register is published on our website once per month on our home page usually around one week after month end. However, the shares from the rights issue are not included in the October enclosure and therefore we did not publish these numbers yet. The reason is, that the BTA’s were converted October...
Read moreJULY – SEPTEMBER · Net sales amounted to MSEK 443.7 (395.3). This corresponds to an increase of 12% for the period, of which the acquired operations account for 10% (MSEK 41.0). · Adjusted EBITDA amounted to MSEK 156.9 (145.8) excluding non-recurring items, costs related to the acquisition of Trimb and restructuring costs totalling MSEK 28.2....
Read moreIn December 2011, Karo Pharma Aktiebolag (”Karo Pharma”) entered into a research collaboration and license agreement with Pfizer, with the purpose of discovering and developing substances that hamper the activity in the nuclear hormone receptor ROR-gamma, for treatment of autoimmune diseases. After completion of the initial research collaboration, Pfizer has conducted the development work in-house,...
Read moreAs previously announced, Karo Pharma Aktiebolag (“Karo Pharma”) has completed a rights issue of 60,700,422 shares, with the purpose of repaying a part of the financing of Karo Pharma’s acquisition of Trimb Holding AB as well as to strengthen Karo Pharma’s financial capacity to carry out acquisitions of companies and product portfolios. As a result...
Read moreNot for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “IMPORTANT INFORMATION” below.
Read moreThe board of directors of Karo Pharma Aktiebolag (”Karo Pharma”) has resolved to postpone the publication of the interim report for the period January – September 2019 to 15 November 2019. The previously announced date for publication was 1 November 2019. The delay is due to the ongoing integration process relating to Karo Pharma’s acquisition...
Read moreRead more
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “IMPORTANT INFORMATION” below.
Read moreRead more
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “IMPORTANT INFORMATION” below.
Read moreSTOCKHOLM, 20 September 2019 At today’s extraordinary general meeting in Karo Pharma, the following resolution was passed. The general meeting resolved, in accordance with the Board of Directors’ proposal, to authorize the Board of Directors to, on one or several occasions until the Annual General Meeting 2020, resolve on a new issue of shares with...
Read moreAs communicated on 12 September 2019, Karo Pharma Aktiebolag (”Karo Pharma”) has completed its acquisition of Trimb Holding AB. The acquisition was mainly financed through a new credit facility and a new bridge loan facility provided by SEB and Swedbank. As previously communicated, Karo Pharma intends to repay the bridge loan facility of MSEK 1,500...
Read moreKaro Pharma Aktiebolag (”Karo Pharma”) today announces that the acquisition of all the shares of Trimb Holding AB (“Trimb”) from Avista Capital Partners and other shareholders for MSEK 3,400, which was signed on 21 June, 2019 and approved by relevant competition authorities on 4 September, 2019, has been completed. The acquisition of Trimb is expected...
Read moreKaro Pharma Aktiebolag (the ”Company” or ”Karo Pharma”) today announces that the acquisition of all the shares of Trimb Holding AB (“Trimb”) from Avista Capital Partners (“Avista”) and other shareholders for MSEK 3,400 (the ”Transaction”), which was signed on 21 June, 2019, has been approved by the Swedish Competition Authority. Previously, clearances have been received...
Read moreThe shareholders of Karo Pharma Aktiebolag, reg. no 556309-3359, are given notice of an Extraordinary General Meeting, to be held on Friday 20 September 2019 at 14:00 CET at Näringslivets Hus, Storgatan 19, Stockholm.
Read moreKaro Pharma Aktiebolag (publ) (“Karo Pharma”) has appointed Jon Johnsson as the new CFO of Karo Pharma, replacing Mats-Olof Wallin, who will retire towards the end of the year. Jon will take on his new position on October 1, 2019. Mats-Olof will collaborate with Jon through the middle of December to secure an orderly transition...
Read moreKaro Pharma Aktiebolag (”Karo Pharma”) today published its interim report for the period January – June 2019. On page 2 of the Swedish language version of the interim report, it was, slightly misleadingly, stated that a directed rights issue of approximately MSEK 1,500 with pre-emptive rights for the shareholders of Karo Pharma is planned. Karo...
Read moreTHE PERIOD AND THE SECOND QUARTER
Read moreKaro Pharma AB (publ) (the ”Company” or ”Karo Pharma”) has today acquired all the shares of Trimb Holding AB (“Trimb”) from Avista Capital Partners (“Avista”) and other shareholders for MSEK 3,400 (the ”Transaction”). The Transaction is expected to contribute positively to Karo Pharma’s market position and create a strong platform for Karo Pharma’s continued growth....
Read moreAt today’s annual general meeting of Karo Pharma, the following decisions were passed. The annual general meeting resolved to adopt the income statement and balance sheet for the group and the parent company. The annual general meeting resolved that available funds, including the earnings for the year, were to be carried forward. The annual general...
Read more· Net sales amounted to MSEK 420.8 (267.1). This corresponds to an increase of 58%. The growth is attributable to products acquired during the period. · Net sales decreased by 6% compared to pro forma numbers for the same period 2018. At comparable exchange rates, sales decreased by 8%. The decrease in net sales is...
Read moreThe shareholders of Karo Pharma Aktiebolag, reg. no. 556309-3359, are given notice of the annual general meeting to be held at 14:00 CET on 16 May 2019, at Näringslivets Hus, Storgatan 19 in Stockholm.
Read moreKaro Pharma publishes its annual report for 2018. Today, on 9 April 2019, Karo Pharma is publishing its annual report for 2018 on the company’s website, www.karopharma.com (http://%20www.karopharma.com). FOR ADDITIONAL INFORMATION, PLEASE CONTACT: Mats-Olof Wallin, CFO, +4676 002 60 10, mats-olof.wallin@karopharma.se ABOUT KARO PHARMA Karo Pharma is a Specialty Pharma company, which develops and markets products for pharmacies...
Read moreSTOCKHOLM on 9 April 2019
Read moreThe Board of Karo Pharma Aktiebolag (publ) (“Karo Pharma”) has appointed Christoffer Lorenzen as the new CEO of Karo Pharma, replacing Peter Blom. Christoffer will take on his new position on July 1, 2019. Up until this date, and effective as of today, Ulf Mattsson assumes the CEO position on an interim basis. Karo Pharma...
Read moreFULL YEAR AND THE FOURTH QUARTER · Net sales amounted to MSEK 1,615.1 (657.6), of which the fourth quarter amounted to MSEK 463.3 (238.7). This corresponds to an increase of 146% for the full year, and 94% for the fourth quarter. A large part of the growth is attributable to products acquired during the period....
Read moreEQT VIII[1] through Karo Intressenter AB (”Karo Intressenter”) proposes, ahead of the Extraordinary General Meeting in Karo Pharma Aktiebolag (”Karo Pharma”) on 14 February 2019 that the Board Member Håkan Åström is reelected and that Bo Jesper Hansen, Erika Henriksson, Vesa Koskinen, Christoffer Lorenzen and Åsa Riisberg are elected as new Board Members with Bo Jesper Hansen as Chairman of the Board.
Read moreThe Board of Directors of Karo Pharma Aktiebolag has concluded to unanimously recommend that the shareholders of Karo Pharma Aktiebolag accept the increased public offer made by EQT VIII, through Karo Intressenter AB.
Read more